Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2017
Price : $35 *
At a glance
- Drugs Rituximab (Primary) ; Temozolomide
- Indications B-cell lymphoma; CNS cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 22 Feb 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
- 01 Jul 2015 Planned End Date changed from 1 May 2017 to 1 May 2016 as reported by ClinicalTrials.gov record.